Your browser doesn't support javascript.
loading
Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.
Kim, Aryun; Kutschke, Amy; Ehmann, David E; Patey, Sara A; Crandon, Jared L; Gorseth, Elise; Miller, Alita A; McLaughlin, Robert E; Blinn, Christina M; Chen, April; Nayar, Asha S; Dangel, Brian; Tsai, Andy S; Rooney, Michael T; Murphy-Benenato, Kerry E; Eakin, Ann E; Nicolau, David P.
Afiliação
  • Kim A; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA aryunkimpharmd@gmail.com.
  • Kutschke A; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Ehmann DE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Patey SA; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Crandon JL; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Gorseth E; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Miller AA; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • McLaughlin RE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Blinn CM; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Chen A; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Nayar AS; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Dangel B; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Tsai AS; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Rooney MT; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Murphy-Benenato KE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Eakin AE; Infection Innovative Medicines, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA.
  • Nicolau DP; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Antimicrob Agents Chemother ; 59(12): 7743-52, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26438502
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Sulfonamidas / Azetidinas / Sideróforos / Farmacorresistência Bacteriana / Antibacterianos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Sulfonamidas / Azetidinas / Sideróforos / Farmacorresistência Bacteriana / Antibacterianos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article